Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3816284 | 0.92 | ALDH1A1 (0.34) | KDM4EALDH1A1MAPTALOX12TSHR | |
| SCHEMBL9819380 | 0.82 | CTSK (0.33) | KDM4EMAPTDPP4ATM | |
| SCHEMBL3817810 | 0.81 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL10385301 | 0.79 | MEN1 (0.35) | KDM4EALDH1A1MAPTALOX12TSHR | |
| SCHEMBL6289946 | 0.77 | ALDH1A1 (0.35) | KDM4EALDH1A1TSHRPPARALMNA | |
| SCHEMBL7208245 | 0.77 | ALDH1A1 (0.41) | KDM4EALDH1A1TSHRPPARALMNA | |
| SCHEMBL2862634 | 0.75 | ALDH1A1 (0.34) | KDM4EALDH1A1MAPTDPP4LMNA | |
| SCHEMBL6287567 | 0.75 | ALDH1A1 (0.33) | ALDH1A1TSHRPPARALMNASMN1; SMN2 | |
| SCHEMBL840862 | 0.71 | ALDH1A1 (0.37) | ALDH1A1DPP4 | |
| SCHEMBL7207337 | 0.71 | ALDH1A1 (0.44) | KDM4EALDH1A1MAPTTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0358092-B1 | 2-AZA-4-(ALKOXYCARBONYL)SPIRO-(4,5)DECAN-3-ONE | LONZA A.G. (CH) | 1991-12-11 | — | — | EP | claimed |
| US-4958044-A | 2-aza-4-(alkoxycarbonyl)spiro[4,5]-decan-3-one | LONZA LTD. (CH) | 1990-09-18 | — | — | US | claimed |
| WO-2010023694-A2 | CRYSTALLINE FORMS OF GABAPENTIN AND PROCESS THEREOF | HIKAL LTD (IN) | 2010-03-04 | — | — | WO | disclosed |
| EP-1603863-B1 | PROCESS FOR THE PREPARATION OF AMINO METHYL CYCLO ALKANE ACETIC ACIDS | HIKAL LTD (IN) | 2010-01-13 | — | — | EP | disclosed |
| US-7635717-B2 | Process for the preparation of amino methyl cyclo alkane acetic acids | HIKAL LIMITED (IN) | 2009-12-22 | — | — | US | disclosed |
| US-20060149099-A1 | Process for the preparation of amino methyl cyclo alkane acetic acids | HIKAL LIMITED | 2006-07-06 | — | — | US | disclosed |
| EP-1603863-A1 | PROCESS FOR THE PREPARATION OF AMINO METHYL CYCLO ALKANE ACETIC ACIDS | Hikal Ltd. (IN) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004046085-A1 | PROCESS FOR THE PREPARATION OF AMINO METHYL CYCLO ALKANE ACETIC ACIDS | HIKAL LTD. (IN) | 2004-06-03 | — | — | WO | disclosed |
| US-5149870-A | Process for the production of 1-(aminomethyl)cyclohexane acetic acid | LONZA LTD. (CH) | 1992-09-22 | — | — | US | disclosed |
| US-5136091-A | Alcoholysis, hydrolysis, transesterification, and hydrogenatio hydrogenation; acid & basic catalysts; anticonvulsants | LONZA LTD. (CH) | 1992-08-04 | — | — | US | disclosed |
| US-5130455-A | Anticonvulsants | LONZA LTD. (CH) | 1992-07-14 | — | — | US | disclosed |
| US-5095148-A | PROCESS FOR THE PRODUCTION OF 1-(AMINOMETHYL)CYCLOHEXANE ACETIC ACID | LONZA LTD. (CH) | 1992-03-10 | — | — | US | disclosed |
| US-4958044-A | 2-aza-4-(alkoxycarbonyl)spiro[4,5]-decan-3-one | LONZA LTD. (CH) | 1990-09-18 | — | — | US | disclosed |
| US-4956473-A | ANTICONVULSANTS | LONZA LTD. (CH) | 1990-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149099-A1 | Process for the preparation of amino methyl cyclo alkane acetic acids | GABRA1, GABRA6, ACMSD | KDM4E 543/4885ALDH1A1 366/4885MAPT 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.